. Treatment following CR to prior therapy demonstrates HR of 0.49 (95% CI: 0.22-1.13). The safety profile of rucaparib was similar to previously reported studies, with grade 3/4 TRAEs occurring in 35.9% of the rucapa...
The late-breaking abstract sessions will highlight new scientific data that has emerged since the original abstract submission.Abstracts previously submitted for the SGO Annual Meeting or SGO Winter Meeting are not eligible for resubmission.Submissions can include preliminary findings if data analysis is ...